Market News

Breaking headlines and analysis across every asset class.

Markets
Kalkine • Oct 2, 2026
UBS Group AG Becomes Substantial Holder in Fleetwood Limited with 5.04% Voting Power

UBS Group AG has announced that it is now a substantial holder in Fleetwood Limited (ASX:FWD), holding a 5.04% voting power stake, effective September 30, 2026. This significant holding, totaling 4,543,565 ordinary shares, is distributed among four UBS entities, with UBS Asset Management (Australia) Ltd holding the largest portion. The filing details how these interests are held, including through fund management, beneficial ownership, prime brokerage, and securities lending agreements.

Markets
Investing.com Nigeria • Oct 2, 2026
Form 4 Meta Platforms Inc For: 1 October By Investing.com

This article from Investing.com announces the Form 4 filing for Meta Platforms Inc. on October 1st. It also provides current market data, including stock indices, commodities, and bond yields, alongside trending stocks and various investment tools available on the platform.

Markets
Investing.com Nigeria • Oct 2, 2026
Form 4 Hyperscale Data Inc For: 1 October By Investing.com

This article reports on a Form 4 filing for Hyperscale Data Inc. dated October 1st. It provides financial market data including indices, commodities, and share prices, alongside popular news headlines. The content also features sections on trending stocks and AI-powered stock picks.

Markets
MarketBeat • Oct 2, 2026
British American Tobacco p.l.c. (NYSE:BTI) Stock Now Rated "Moderate Buy" by Wall Street Analysts

British American Tobacco p.l.c. (NYSE:BTI) has received an average rating of "Moderate Buy" from Wall Street analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $68.10, surpassing the current share price of $53.15. Despite some mixed analyst views, the company's stock performance and institutional ownership are highlighted, along with recent earnings that missed consensus estimates.

Markets
AD HOC NEWS • Oct 1, 2026
Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13

Amgen reported positive Phase 3 results for dazodalibep in systemic Sjogren's disease on September 22, 2026, which showed statistically significant and clinically meaningful improvement. The company also announced strong second-quarter revenue of USD 10.05 billion, up 9.50 percent, and maintained its full-year adjusted earnings-per-share guidance. Amgen stock was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026, slightly down from its prior close, with its next earnings date scheduled

Markets
Simply Wall Street • Oct 1, 2026
Elevance Health (ELV) Is Back In The Spotlight, What Is Drawing Attention?

Elevance Health (ELV) has recently drawn attention due to its share price movement, with the stock closing at US$388.82. Despite some softer short-term trading, the company's year-to-date and one-year returns are positive. The most popular narrative suggests ELV is 14% undervalued with a fair value of $451.38, driven by the expected positive impact of AI and digital platforms on cost management and net margins.

Markets
MarketBeat • Oct 1, 2026
JOYY Inc. Sponsored ADR (NASDAQ:JOYY) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Seven sell-side analysts have given JOYY Inc. Sponsored ADR (NASDAQ:JOYY) a consensus "Moderate Buy" rating, with an average 12-month price target of $83.40, which is higher than its current trading price. The company recently increased its quarterly dividend to $1.55 per share, resulting in a 7.7% yield, though its payout ratio is high at 142.72%. Institutional investors and hedge funds own a significant portion of JOYY's stock, which is currently trading near its 12-month high.

Markets
Investing.com • Oct 1, 2026
Morgan Stanley initiates D.R. Horton stock coverage with Equalweight rating

Morgan Stanley has initiated coverage on D.R. Horton Inc. (NYSE:DHI) with an Equalweight rating and a price target of $151.00. The firm highlighted D.R. Horton's strong position in the homebuilding market due to its scale, affordable product mix, and strategic land control, which enable it to maintain volumes despite challenging affordability. However, Morgan Stanley also noted potential risks, including the company's exposure to rate-sensitive first-time buyers, which could pressure margins if

Markets
Investing.com Canada • Oct 1, 2026
B.Riley reiterates Kymera Therapeutics stock rating on new trial data

B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (NASDAQ: KYMR) after the company presented new data from its oral STAT6 degrader KT-621 at EADV’26. The stock has seen a 104% increase over the past year, reflecting strong investor interest. Several other analysts, including Stifel, BofA Securities, Guggenheim, and Piper Sandler, have also recently increased their price targets and maintained Buy or Overweight ratings, indicating broad positive sentiment driv

Get Headlines in Your Inbox

One email a day with the market-moving stories you actually need to read.